AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Drugdiscoverytrends

Published November 10, 2026

Psychedelic pioneer Compass files for FDA approval as rivals close in

Read the full story at Drugdiscoverytrends

psychedelics , treatment-resistant depression, Usona Institute. About The Author. Brian Buntz. As the pharma and biotech editor at WTWH Media, Brian.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech